Suzuki H - Search Results

1

Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.

Saito M, Suzuki H, Kono K, Takenoshita S, Kohno T. Saito M, et al. Among authors: suzuki h. Surg Today. 2018 Jan;48(1):1-8. doi: 10.1007/s00595-017-1497-7. Epub 2017 Mar 9. Surg Today. 2018. PMID: 28280984 Review.

2

Clinical evaluation of dendritic cells vaccination for advanced cancer patients at Fukushima Medical University.

Nakamura I, Kanazawa M, Sato Y, Irisawa A, Takagi T, Ogata T, Kashimura S, Kenjo A, Suzuki H, Shibata M, Shimura T, Ohira H, Goto M, Takenoshita S, Ohto H. Nakamura I, et al. Among authors: suzuki h. Fukushima J Med Sci. 2012;58(1):40-8. doi: 10.5387/fms.58.40. Fukushima J Med Sci. 2012. PMID: 22790891 Free article.

3

[Myeloid-derived suppressor cells in cancer patients].

Gonda K, Shibata M, Nakamura I, Kenjo A, Ohtake T, Yasuda M, Suzuki S, Suzuki H, Watanabe T, Fujimori K, Gotoh M, Takenoshita S. Gonda K, et al. Among authors: suzuki h, suzuki s. Gan To Kagaku Ryoho. 2012 Nov;39(12):1797-9. Gan To Kagaku Ryoho. 2012. PMID: 23267890 Japanese.

4

[I. History of Immunotherapy and Cancer Vaccine for Lung Cancer].

Suzuki H, Takagi H, Owada Y, Watanabe Y, Inoue T, Fukuhara M, Yamaura T, Muto S, Okabe N, Hasegawa T, Shio Y. Suzuki H, et al. Gan To Kagaku Ryoho. 2017 Aug;44(8):646-649. Gan To Kagaku Ryoho. 2017. PMID: 28860434 Japanese. No abstract available.

5

Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma.

Matsumura Y, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Hasegawa T, Hoshino M, Osugi J, Higuchi M, Suzuki H. Matsumura Y, et al. Among authors: suzuki h. Interact Cardiovasc Thorac Surg. 2017 Nov 1;25(5):690-695. doi: 10.1093/icvts/ivx207. Interact Cardiovasc Thorac Surg. 2017. PMID: 29049789

6

Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.

Saito M, Saito K, Shiraishi K, Maeda D, Suzuki H, Minamiya Y, Kono K, Kohno T, Goto A. Saito M, et al. Among authors: suzuki h. Mol Clin Oncol. 2018 Feb;8(2):310-314. doi: 10.3892/mco.2017.1536. Epub 2017 Dec 12. Mol Clin Oncol. 2018. PMID: 29435295 Free PMC article.

7

[Recent Advances in Immunotherapy for Non-Small Cell Lung Cancer].

Muto S, Suzuki H. Muto S, et al. Among authors: suzuki h. Gan To Kagaku Ryoho. 2018 Feb;45(2):212-216. Gan To Kagaku Ryoho. 2018. PMID: 29483407 Japanese.

8

Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.

Hayasaka K, Shiono S, Matsumura Y, Yanagawa N, Suzuki H, Abe J, Sagawa M, Sakurada A, Katahira M, Takahashi S, Endoh M, Okada Y. Hayasaka K, et al. Among authors: suzuki h. Ann Thorac Surg. 2018 Jun;105(6):1648-1654. doi: 10.1016/j.athoracsur.2018.01.052. Epub 2018 Feb 24. Ann Thorac Surg. 2018. PMID: 29486179

9

Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.

Saito M, Shiraishi K, Goto A, Suzuki H, Kohno T, Kono K. Saito M, et al. Among authors: suzuki h. Jpn J Clin Oncol. 2018 Jul 1;48(7):603-608. doi: 10.1093/jjco/hyy068. Jpn J Clin Oncol. 2018. PMID: 29762727 Review.

10

Pseudoprogression and Rapid Response to Pembrolizumab in a Patient with Advanced Lung Adenocarcinoma with Loss of Epidermal Growth Factor Receptor Gene Mutation after Tyrosine Kinase Inhibitor Therapy.

Yamaura T, Suzuki H. Yamaura T, et al. Among authors: suzuki h. J Thorac Oncol. 2018 Oct;13(10):e209-e210. doi: 10.1016/j.jtho.2018.05.021. J Thorac Oncol. 2018. PMID: 30244857 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14,927 results

Search Page